Evidence map›Paper›PMID 28831696›Full record

ArticleJournal of assisted reproduction and genetics2017

BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.

I A P Derks-Smeets, T C van Tilborg, A van Montfoort, L Smits, H L Torrance, M Meijer-Hoogeveen, F Broekmans, J C F M Dreesen, A D C Paulussen, V C G Tjan-Heijnen and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of assisted reproduction and genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Double jeopardy: howFrontiers in cell and developmental biology · 2026
    Review
  4. Susceptibility of Brca1Cancer science · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. BRCA, infertility, and fertility preservation: a review for counseling.Journal of assisted reproduction and genetics · 2023
    Review
  10. Article
  11. The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.Reproductive sciences (Thousand Oaks, Calif.) · 2023
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

I A P Derks-SmeetsDepartment of Clinical Genetics, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
T C van TilborgDepartment of Reproductive Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
A van MontfoortGROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
L SmitsDepartment of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
H L TorranceDepartment of Reproductive Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
M Meijer-HoogeveenDepartment of Reproductive Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
F BroekmansDepartment of Reproductive Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
J C F M DreesenDepartment of Clinical Genetics, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
A D C PaulussenDepartment of Clinical Genetics, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
V C G Tjan-HeijnenGROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
I HommingaDepartment of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
M M J van den BergCenter for Reproductive Medicine, Academic Medical Center, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.
M G E M AusemsDepartment of Genetics, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
M de RyckeCenter for Medical Genetics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium.
C E M de Die-SmuldersDepartment of Clinical Genetics, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
W VerpoestCenter for Reproductive Medicine, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium.
R van GoldeGROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. ron.van.golde@mumc.nl.
Maastricht University · NLUniversity Medical Center · USUtrecht University · NLUniversitair Ziekenhuis Brussel · BEUniversity Medical Center Utrecht · NLAcademic Medical Center · NLUniversity of Groningen · NL

Funding

KWF Kankerbestrijding 2011-5249
6 · The paper itself

Abstract

purposeThe aim of this study was to determine whether BRCA1/2 mutation carriers produce fewer mature oocytes after ovarian stimulation for in vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD), in comparison to a PGD control group.

methodsA retrospective, international, multicenter cohort study was performed on data of first PGD cycles performed between January 2006 and September 2015. Data were extracted from medical files. The study was performed in one PGD center and three affiliated IVF centers in the Netherlands and one PGD center in Belgium. Exposed couples underwent PGD because of a pathogenic BRCA1/2 mutation, controls for other monogenic conditions. Only couples treated in a long gonadotropin-releasing hormone (GnRH) agonist-suppressive protocol, stimulated with at least 150 IU follicle stimulating hormone (FSH), were included. Women suspected to have a diminished ovarian reserve status due to chemotherapy, auto-immune disorders, or genetic conditions (other than BRCA1/2 mutations) were excluded. A total of 106 BRCA1/2 mutation carriers underwent PGD in this period, of which 43 (20 BRCA1 and 23 BRCA2 mutation carriers) met the inclusion criteria. They were compared to 174 controls selected by frequency matching.

resultsThirty-eight BRCA1/2 mutation carriers (18 BRCA1 and 20 BRCA2 mutation carriers) and 154 controls proceeded to oocyte pickup. The median number of mature oocytes was 7.0 (interquartile range (IQR) 4.0-9.0) in the BRCA group as a whole, 6.5 (IQR 4.0-8.0) in BRCA1 mutation carriers, 7.5 (IQR 5.5-9.0) in BRCA2 mutation carriers, and 8.0 (IQR 6.0-11.0) in controls. Multiple linear regression analysis with the number of mature oocytes as a dependent variable and adjustment for treatment center, female age, female body mass index (BMI), type of gonadotropin used, and the total dose of gonadotropins administered revealed a significantly lower yield of mature oocytes in the BRCA group as compared to controls (p = 0.04). This finding could be fully accounted for by the BRCA1 subgroup (BRCA1 mutation carriers versus controls p = 0.02, BRCA2 mutation carriers versus controls p = 0.50).

conclusionsOvarian response to stimulation, expressed as the number of mature oocytes, was reduced in BRCA1 but not in BRCA2 mutation carriers. Although oocyte yield was in correspondence to a normal response in all subgroups, this finding points to a possible negative influence of the BRCA1 gene on ovarian reserve.

Indexed as

Fertilization in VitroAdultBRCA1 ProteinBRCA2 ProteinFemaleFollicle Stimulating HormoneGonadotropinsHeterozygoteHumansIn Vitro Oocyte Maturation TechniquesMutationOocytesOvarian ReserveOvulation InductionPregnancyPregnancy RateBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanFollicle Stimulating HormoneGonadotropinsBRCA1/2 mutationsIVFMature oocytesOvarian reservePreimplantation genetic diagnosis

Identifiers

PMID28831696
PMCPMC5699993
OpenAlexW2748130530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.